Physician profile
Reeli Reinu
NPI 1609884253
$427,298.28
in general payments reported to CMS, 2019-2025
32 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21K · 2022: $51K · 2023: $87K · 2024: $128K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $240K · Travel and Lodging: $64K · Consulting Fee: $32K · Food and Beverage: $19K · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $239,562.00 |
| Travel and Lodging | $64,268.73 |
| Consulting Fee | $32,120.00 |
| Food and Beverage | $18,599.17 |
| Education | $389.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $353,274.03 | 2021-2025 | Tremfya, Simponi Aria |
| Janssen Scientific Affairs, LLC | $59,854.01 | 2021-2022 | |
| Abbvie INC. | $2,381.69 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,863.44 | 2021-2024 | Cabtreo, Jublia, Arazlo |
| Dermavant Sciences, INC. | $1,699.78 | 2022-2024 | Vtama |
| Incyte Corporation | $1,475.06 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $894.98 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $789.41 | 2021-2025 | |
| Lilly USA, LLC | $686.77 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $637.34 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $612.29 | 2021-2025 | |
| Leo Pharma INC. | $512.82 | 2021-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $408.75 | 2022-2025 | Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $392.30 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $359.73 | 2021-2025 | Nemluvio, Aklief |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $326.47 | 2022-2025 | Sotyktu |
| Amgen INC. | $275.96 | 2021-2025 | Otezla, Otezla |
| Almirall LLC | $219.67 | 2021-2025 | Klisyri, Seysara |
| Organon LLC | $108.59 | 2025 | Vtama |
| Pfizer INC. | $102.14 | 2024-2025 | |
| Organogenesis INC. | $92.50 | 2025 | Affinity, Cygnus Dual, Simplimax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.31 | 2023-2025 | Spevigo |
| Biofrontera INC. | $60.84 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $38.21 | 2021-2024 | Erivedge |
| Mayne Pharma Commercial LLC | $27.88 | 2023 | |
| Sanofi-Aventis U.S. LLC | $23.77 | 2021 | |
| Strata Skin Sciences, INC. | $22.78 | 2024 | Xtrac |
| Ascensia Diabetes Care US INC. | $22.70 | 2024 | |
| Journey Medical Corporation | $21.58 | 2022 | |
| Fresenius Kabi USA, LLC | $20.60 | 2024 | Idacio |
| Botanix Sb INC | $16.71 | 2025 | Sofdra |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reeli Reinu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.